Contents

Bilateral Optic Nerve Involvement in Immunoglobulin G4Related Ophthalmic Disease

Update item information
Title Journal of Neuro-Ophthalmology, March 2014, Volume 34, Issue 1
Publisher Lippincott, Williams & Wilkins
Date 2014-03
Type Text
Language eng
Rights Management © North American Neuro-Ophthalmology Society
Publication Type Journal Article
ARK ark:/87278/s67979sg
Setname ehsl_novel_jno
Date Created 2015-03-24
Date Modified 2020-03-03
ID 227572
Reference URL https://collections.lib.utah.edu/ark:/87278/s67979sg

Page Metadata

Title Bilateral Optic Nerve Involvement in Immunoglobulin G4Related Ophthalmic Disease
Creator Takahashi, Yasuhiro; Kitamura, Atsuko; Kakizaki, Hirohiko
Affiliation Department of Ophthalmology (YT, HK), Aichi Medical University, Nagakute, Aichi, Japan; and Department of Pathology (AK), Aichi Medical University Hospital, Nagakute, Aichi, Japan
Subject Biopsy; Follow-Up Studies; Glucocorticoids; Humans; Immunoglobulin G; Injections, Intravenous; Magnetic Resonance Imaging; Male; Middle Aged; Optic Nerve Diseases; Orbital Diseases; Prednisolone; Tomography, X-Ray Computed
Abstract To describe a presumptive case of immunoglobulin G4-related ophthalmic disease (IgG4-ROD) with bilateral optic nerve involvement and to review the clinical features of this entity. A 62-year-old man presented with bilateral blurred vision. He had a history of sinus surgery, and a biopsy specimen showed dense infiltration of IgG4-positive plasma cells. His visual acuity was 20/25, right eye, and 20/125, left eye. Serologies demonstrated elevated serum levels of IgG and IgG4, and computed tomography showed masses surrounding both optic nerves at the orbital apices and bilaterally enlarged infraorbital nerves. The patient underwent 2 cycles of intravenous pulse steroid therapy followed by a taper of oral steroids Three months later, vision was 20/20 in each eye and, while the serum level of IgG was within normal limits, the IgG4 level remained elevated. IgG4-ROD may involve the optic nerves resulting in vision loss. Although steroid administration is the primary treatment for this entity, slow tapering is essential to avoid relapse.
OCR Text Show
Publisher Lippincott, Williams & Wilkins
Date 2014-03
Type Text
Language eng
Rights Management © North American Neuro-Ophthalmology Society
Publication Type Journal Article
Setname ehsl_novel_jno
Date Created 2015-03-24
Date Modified 2015-03-24
ID 227543
Reference URL https://collections.lib.utah.edu/ark:/87278/s67979sg/227543